• Online Features  This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on Web of Science (3)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Where Do We Go From Here?

Patricia L. Myskowski, MD

Arch Dermatol. 1993;129(10):1320-1323.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

KAPOSI'S SARCOMA (KS) has long been a clinical and therapeutic challenge. In the century since Moritz Kaposi's first description of this disease in elderly eastern European men, a number of clinical variants have been described along with multiple theories to explain its distribution in various unique and seemingly unrelated populations. To this day, there is still debate about the cell of origin of KS, the role of infectious agent(s), and even whether KS is a genuine malignancy or merely a reactive hyperplasia. A variety of antitumor approaches have been used,^1,2 but optimal therapy may depend on answers to some of the more basic questions about the cause and pathogenesis of KS.

Epidemiology offers the first clues. The seemingly disparate groups (classic KS; endemic, both in central Africa and, recently, Greece³; human immunodeficiency virus (HIV)-associated KS; and KS in otherwise immunosuppressed individuals) can best be explained by the notion . . . [Full Text PDF of this Article]

Author Affiliations

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?